📦 Bulk Ordering Now Live - 10-Packs + Up To 15% Off · See Tiers
Research Grade
Free shipping over $150
ENOS
Peptides

Retatrutide Compound Reference

Published · Last updated · Publisher: ENOS Labs USA

What is Retatrutide?

Retatrutide (LY3437943) is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It has been studied in phase 2 trials in obesity, type 2 diabetes and fatty liver disease and in the phase 3 TRIUMPH program. It is not an FDA approved drug as of this page's last update.

Synonyms
LY3437943; GIP, GLP-1 and glucagon receptor triple agonist
Classification
Investigational single peptide agonist of the GIP, GLP-1 and glucagon receptors

What is Retatrutide?

Retatrutide is a modified peptide developed by Eli Lilly that combines activity at three receptors in one molecule. It sits in the incretin based drug research family alongside single GLP-1 receptor agonists and the dual GIP and GLP-1 agonist tirzepatide.

Research context

Clinical research has focused on body weight, glycemic measures and liver fat. Phase 2 results were published in 2023 in obesity and type 2 diabetes, a liver fat substudy followed in 2024, and the first phase 3 obesity results (TRIUMPH-1) were published in 2026.

Mechanisms being investigated

  • GLP-1 and GIP receptor activation, the incretin pathways shared with earlier agents.
  • Glucagon receptor activation, investigated for its effects on energy expenditure and liver fat.

Research status

Approval status: Investigational (clinical trials). Highest evidence tier in the cited literature: clinical trials.

Investigational. Retatrutide is in clinical development and has not received FDA approval as of the last updated date on this page. Research grade material supplied for laboratory use is not the clinical trial drug product.

Established findings

  • Its receptor targets and that it has completed phase 2 trials with published results.
  • Registered phase 3 trials exist on ClinicalTrials.gov.

Preliminary or experimental findings

  • Long term safety and outcome data, which phase 3 programs are still generating.
  • How the glucagon component contributes relative to the incretin components.

Chemical reference information

No PubChem record with verified formula and weight was found for this material, so none is shown.

Testing considerations

  • Large modified peptide: identity by high resolution mass spectrometry is important because small modifications shift the mass.
  • Lipidation and non natural residues make HPLC method conditions especially relevant to purity comparisons.

General methods are explained in purity versus identity testing.

What is still unknown

  • Regulatory outcome.
  • Durability and safety beyond trial follow up periods.

Related resources

ENOS catalog listing: GLP-3 "RET" 10MG, GLP-3 "RET" 20MG, GLP-3 "RET" 30MG

Research use limitations

This page summarizes published research and regulatory status. It is not medical advice and does not describe any use in people. Material supplied by ENOS Labs USA is for in-vitro laboratory research only and is not a drug product, even where a related drug has been approved.

To continue, see GLP receptor agonist research, how to read a certificate of analysis, why purity and identity are separate tests, the compound directory and the peptide testing glossary.

References

Each source below was opened and checked against its PubMed, ClinicalTrials.gov or PubChem record. Links open in a new tab.

  1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (PMID 37366315)The New England Journal of Medicine, 2023 · PubMed
  2. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (PMID 37385280)The Lancet, 2023 · PubMed
  3. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (PMID 38858523)Nature Medicine, 2024 · PubMed
  4. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (PMID 42814954)The New England Journal of Medicine, 2026 · PubMed
  5. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (NCT05929066)ClinicalTrials.gov · NIH National Library of Medicine
For Research Use Only

These products are sold strictly for in-vitro laboratory research and are not intended for human consumption, diagnosis, treatment, or any therapeutic use. Purchaser must be 18 years of age or older and confirms they are a qualified researcher.